pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,141 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1894Endpoints1467Fierce Biotech779BioSpace768BioPharma Dive555raps257onclive165fda recalls
therapy area
allOncology13097Rare Disease3403Immunology3069Cardiology2870Hematology2337Pulmonology2300Vaccines
  • FDA rejects Capricor's Duchenne cell therapy again, citing major trial flaws
    Capricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy was denied by the FDA for a second time. The agency highlighted significant issues with the trial design and data, le…
    Endpoints · 18h agoRegulatoryNegative↗ source
  • Biopharma newsletter released despite tech outages, highlights Washington political news
    The latest edition of a biopharma newsletter was published even though the week was marked by several technology outages. The issue notes that the most significant story came from Washington, wher…
    Endpoints · 8h agoNeutral↗ source
← prev
page 1 of 86
next →
126
fda medwatch117
globenewswire health73
fda press62
1892
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • Revolution Medicines reports strong data for KRAS-targeted pancreatic cancer drug amid rising competition
    Revolution Medicines presented encouraging results for its KRAS‑targeted therapy aimed at pancreatic cancer at a recent industry meeting. The company highlighted the potency of the drug in preclini…
    Endpoints · 1d agoPositive readoutNeutral↗ source
  • Merck's sac-TMT antibody-drug conjugate achieves positive Phase 3 results in gastric cancer
    Merck announced that its experimental antibody-drug conjugate sacituzumab-TMT (sac-TMT) met primary endpoints in a pivotal Phase 3 trial in patients with gastric cancer. The trial outcome represen…
    Endpoints · 1d agoPositive readoutPositive↗ source
  • Lawmakers split on US restrictions for China biotech investments
    Ahead of the upcoming Democrat-controlled Congress, lawmakers from both parties are articulating new positions on whether the United States should limit investments in China's rapidly growing biote…
    Endpoints · 23h agoRegulatoryNeutral↗ source
  • Celldex drops eczema antibody barzolvolimab after Phase 2 failure
    Celldex Therapeutics said it is ending development of its monoclonal antibody barzolvolimab as a treatment for eczema. The Phase 2 study did not show a statistically significant reduction in itchi…
    Endpoints · 1d agoNegative readoutNegative↗ source
  • Heraeus Medevio issues recall of vascular guidewires over coating safety risk
    The FDA's Center for Devices and Radiological Health has posted an Early Alert warning about a potentially high‑risk issue with certain vascular guidewires. The alert notes that the coating on the…
    fda medwatch · 1d agoRegulatoryNegative↗ source
  • ICH Q1 Stability Testing Guideline Revision Expected Within Weeks
    The International Council for Harmonization announced that the revised ICH Q1 stability testing guideline has been adopted and will be published soon. The new version will be issued as a Step 4 gu…
    raps · 1d agoRegulatoryNeutral↗ source
  • Commenters urge FDA to allow flexible trial designs for rare diseases, questioning RCT emphasis
    Stakeholders who submitted comments to the FDA’s public docket on statistical methods for rare disease studies emphasized the need for greater flexibility in how trials are designed and what types…
    raps · 1d agoRegulatoryNeutral↗ source
  • Novo announces layoff of 215 New Jersey staff as Bausch + Lomb trial misses endpoint
    Novo Pharma said it will cut 215 positions at its Plainsboro, New Jersey facility, with the reductions slated to begin in February 2027. The move adds to a series of recent workforce reductions ac…
    Endpoints · 1d agoLayoffsNegative↗ source
  • Teva appoints interim R&D head as Eric Hughes departs
    Teva announced that its global research and development leader and chief medical officer, Eric Hughes, has left the company. Hughes, who joined Teva in 2022 after a senior role at Vertex, will be s…
    Endpoints · 1d agoNeutral↗ source
  • FDA outlines inspection focus on risk management for combination product manufacturers
    FDA officials said that manufacturers using a streamlined CGMP approach for combination products should expect the agency to closely scrutinize their risk management activities. The remarks were d…
    raps · 1d agoRegulatoryNeutral↗ source
  • CNS players discuss deals, psychiatry challenges and Alzheimer focus at Jefferies London conference
    The Jefferies Global Healthcare conference in London brought together several companies active in the central nervous system and psychiatry sectors. Attendees heard updates from a range of drugmake…
    Endpoints · 1d agoNeutral↗ source
  • FDA faces push for flexible rare-disease trial designs as commissioner's nomination withdrawn
    The FDA’s weekly briefing highlighted several notable developments, including the sudden withdrawal of the Trump administration’s nominee for FDA commissioner at the last minute. The agency also a…
    raps · 1d agoRegulatoryNeutral↗ source
  • FDA approves treatments for four rare diseases; Pfizer inks $2.6 billion China licensing deal for CAR‑T therapy
    The U.S. Food and Drug Administration has granted approval for drugs targeting four distinct rare diseases, expanding therapeutic options for patients with limited treatment choices. In a separate…
    raps · 2d agoApprovalPositive↗ source
  • Congressional biotech panel cautions on rising China licensing deals
    A bipartisan congressional commission that advises on U.S. biotech competitiveness is concluding its work with a focus on partnerships with Chinese firms. The panel highlighted the growing number…
    Endpoints · 2d agoRegulatoryNegative↗ source
  • Sanofi's Infilbray receives first U.S. approval for treating neurological symptoms of Gaucher disease
    Sanofi announced that the U.S. Food and Drug Administration has granted approval for Infilbray, a therapy aimed at the neurological manifestations of Gaucher disease, a rare genetic disorder. The…
    Endpoints · 2d agoApprovalPositive↗ source
  • Sanofi explores acquisition of Insmed in potential major biopharma deal
    Sanofi is reportedly evaluating a purchase of the U.S. drugmaker Insmed, according to a Bloomberg News report. The potential transaction would rank among the largest biopharma acquisitions in rece…
    Endpoints · 2d agoDealNeutral↗ source
  • FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolio
    Regeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…
    Endpoints · 2d agoApprovalPositive↗ source
  • AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor deal
    AbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…
    Endpoints · 2d agoDealPositive↗ source
  • Eli Lilly breaks ground on $3.5 billion Pennsylvania plant to produce obesity drugs
    Eli Lilly has begun construction of a new manufacturing facility in the Lehigh Valley region of Pennsylvania. The $3.5 billion plant is slated to increase capacity for the company’s obesity drug po…
    Endpoints · 2d agoNeutral↗ source
  • Chinese AI lab MegaRobo secures almost $200 million in funding as Isomorphic strikes partnership with Merck
    Chinese AI and lab-automation company MegaRobo announced it has raised close to $200 million, according to a post on WeChat. The capital injection is intended to expand the firm’s artificial-intel…
    Endpoints · 2d agoDealPositive↗ source
  • Oura announces acquisition of Counsel Health at HLTH conference
    Oura, known for its wearable health tracker, disclosed that it is purchasing Counsel Health, a company that provides health data services. The announcement was made during the HLTH conference, whe…
    Endpoints · 2d agoDealPositive↗ source
  • Novartis reports mid-stage eczema drug success, plans to restart autoimmune CAR-T trials and narrows sales growth outlook
    Novartis said its experimental eczema treatment achieved a positive result in a mid-stage study, marking the company's first major clinical milestone in the skin-disorder area this year. The compa…
    Endpoints · 2d agoPositive readoutNeutral↗ source
  • Outset Medical issues safety alert for Tablo dialysis system power cords overheat risk
    The FDA’s Center for Devices and Radiological Health has posted an Early Alert after learning that certain power cords used with Outset Medical’s Tablo hemodialysis consoles and the TabloCart with…
    fda medwatch · 2d agoRegulatoryNeutral↗ source